Processa Pharmaceuticals Inc (PCSA) Stock Price, Quote & News

Company Profile

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical t...

Industry: Biotechnology

Sector: Healthcare

Phone: 443 776 3133

Fax: 443 288 4420

Website: www.processapharmaceuticals.com

Address:

7380 Coca Cola Drive, Suite 106, Hanover, United States

TheDrunkTrader69 Aug. 18 at 1:08 PM

$PCSA I can see some strong buys coming very soon, some say there are no whales but I know better its gonna get crazy 😜

0 · Reply

littlegretti Aug. 17 at 4:08 PM

$PCSA What is your take away on the sold shares for crypto. I’m bullish for the company but trying to understand if they were going to have news soon why sell at .23. It could be just a drop in the bucket for them. I understand the fomo into crypto because of the current administration. Just makes me think they might not give great news till like mid November or something. I don’t know. Just talking.

1 · Reply

Jwa68 Aug. 16 at 5:58 PM

$PCSA Wonder which one of Alexandre Dreyfus's companies he may intend to merge here for the public shell and Nasdaq listing. Going to be interesting to see if they can get quorum and shareholder approval for the authorized increase to 1B shares and a reverse split of up to 1 for 50 which are likely prerequisite to a deal. Absent approval, one may assume a deal will not be able to be consumated. Surely Alexandre wants a clean Nasdaq shell with no liabilities. Be interesting to see what they do with the biotech assets, albeit they aren't worth much and 6422 is encumbered in a lawsuit. Alexandre is a big deal, highly accomplished. May be a future opportunity post a transaction and reverse split.

0 · Reply

race2zero Aug. 15 at 11:31 PM

$PCSA sorry gentlemen, a little late post today. Just got to Vegas, was hoping for a little pump so I could have more fun… but red again. Oh well, maybe next week

1 · Reply

TheDrunkTrader69 Aug. 15 at 7:10 PM

$PCSA Pay attention, this is what whales wait for , big buys should follow.

2 · Reply

Trex28 Aug. 15 at 7:06 PM

$PCSA This is more of what I thought the stock would do in terms of a slow bleed off. I have been away all day, so I'm not looking at specific buy or sell volume... but I imagine the next hour will be very telling heading into next week.

0 · Reply

TheDrunkTrader69 Aug. 15 at 7:01 PM

$PCSA Adding

0 · Reply

littlegretti Aug. 15 at 6:54 PM

$PCSA That should complete last wave. (Maybe lol) we got good price action

0 · Reply

P_trades84 Aug. 15 at 2:39 PM

$ATCH .17s- highs of .27, watching to reload dips $CODX Swing from .26s to .40s Adding a little $PCSA down here for a lotto for upcoming news after that 13D the other day

0 · Reply

race2zero Aug. 15 at 1:09 PM

$PCSA whoop whoop! Woke up to being up $18 on this 0.14% premarket run!

0 · Reply

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

Jul 1, 2025, 9:00 AM EDT - 6 weeks ago

Processa Pharmaceuticals Provides Portfolio and Business Update

Jun 17, 2025, 12:26 PM EDT - 2 months ago

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jun 17, 2025, 9:00 AM EDT - 2 months ago

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

Jun 13, 2025, 8:00 AM EDT - 2 months ago

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

May 30, 2025, 9:00 AM EDT - 2 months ago

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

Apr 15, 2025, 8:00 AM EDT - 4 months ago

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Mar 18, 2025, 8:30 AM EDT - 5 months ago

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Feb 7, 2025, 8:00 AM EST - 6 months ago

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Jan 30, 2025, 5:17 PM EST - 7 months ago

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Jan 27, 2025, 8:30 PM EST - 7 months ago

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Oct 2, 2024, 4:05 PM EDT - 11 months ago

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Jun 11, 2024, 8:20 AM EDT - 1 year ago

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

May 6, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Mar 25, 2024, 8:15 AM EDT - 1 year ago

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

Feb 21, 2024, 8:15 AM EST - 1 year ago

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 14, 2024, 1:00 PM EST - 1 year ago

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Feb 6, 2024, 8:30 AM EST - 1 year ago

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 1, 2024, 4:22 PM EST - 1 year ago

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Jan 26, 2024, 9:04 AM EST - 1 year ago

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Jan 25, 2024, 11:29 AM EST - 1 year ago

What made Processa Pharmaceuticals stock nearly triple on Thursday?

Jan 25, 2024, 8:30 AM EST - 1 year ago

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Jan 19, 2024, 7:45 AM EST - 1 year ago

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Jan 18, 2024, 7:45 AM EST - 1 year ago

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Jan 2, 2024, 5:06 PM EST - 1 year ago

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

Dec 19, 2023, 9:00 AM EST - 1 year ago

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

Dec 13, 2023, 9:00 AM EST - 1 year ago

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

Nov 30, 2023, 8:15 AM EST - 1 year ago

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

Nov 29, 2023, 8:15 AM EST - 1 year ago

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

Nov 13, 2023, 1:40 PM EST - 1 year ago

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Nov 9, 2023, 8:15 AM EST - 1 year ago

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

Nov 1, 2023, 8:15 AM EDT - 1 year ago

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Oct 13, 2023, 1:08 PM EDT - 2 years ago

Processa Pharmaceuticals to Present at the ThinkEquity Conference

Sep 6, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 17, 2023, 8:05 AM EDT - 2 years ago

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Aug 10, 2023, 4:15 PM EDT - 2 years ago

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

Aug 8, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

Jun 14, 2023, 4:15 PM EDT - 2 years ago

Next Generation Chemotherapy: Improved Treatment for More Patients

May 22, 2023, 8:05 AM EDT - 2 years ago

Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress

May 18, 2023, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

Apr 28, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

Mar 31, 2023, 4:14 PM EDT - 2 years ago

Processa Pharmaceuticals, Inc. (PCSA) Q4 2022 Earnings Call Transcript

Mar 30, 2023, 4:01 PM EDT - 2 years ago

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

Mar 23, 2023, 8:30 AM EDT - 2 years ago

Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

Mar 17, 2023, 8:30 AM EDT - 2 years ago

Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

Mar 7, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Feb 21, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies

Feb 15, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules

TheDrunkTrader69 Aug. 18 at 1:08 PM

$PCSA I can see some strong buys coming very soon, some say there are no whales but I know better its gonna get crazy 😜

0 · Reply

littlegretti Aug. 17 at 4:08 PM

1 · Reply

Jwa68 Aug. 16 at 5:58 PM

0 · Reply

race2zero Aug. 15 at 11:31 PM

$PCSA sorry gentlemen, a little late post today. Just got to Vegas, was hoping for a little pump so I could have more fun… but red again. Oh well, maybe next week

1 · Reply

TheDrunkTrader69 Aug. 15 at 7:10 PM

$PCSA Pay attention, this is what whales wait for , big buys should follow.

2 · Reply

Trex28 Aug. 15 at 7:06 PM

0 · Reply

TheDrunkTrader69 Aug. 15 at 7:01 PM

$PCSA Adding

0 · Reply

littlegretti Aug. 15 at 6:54 PM

$PCSA That should complete last wave. (Maybe lol) we got good price action

0 · Reply

P_trades84 Aug. 15 at 2:39 PM

$ATCH .17s- highs of .27, watching to reload dips $CODX Swing from .26s to .40s Adding a little $PCSA down here for a lotto for upcoming news after that 13D the other day

0 · Reply

race2zero Aug. 15 at 1:09 PM

$PCSA whoop whoop! Woke up to being up $18 on this 0.14% premarket run!

0 · Reply

littlegretti Aug. 15 at 12:07 PM

$PCSA Waiting on milestone announcement. CEO he has been in talks for partnership. And we are in that time zone of when he said should know something in a couple months. He said that almost a couple months ago. Signed a binding term sheet with Intact Therapeutics, offering them an exclusive option to license PCS12852 (a 5-HT4 receptor agonist). Deal potentially includes $452.5M in milestones, royalties, and a 3.5% equity stake

0 · Reply

race2zero Aug. 14 at 8:57 PM

$PCSA pretty red day across the board…same thing different day here again +\- only a percent or two

0 · Reply

Trex28 Aug. 14 at 3:24 PM

$PCSA I was concerned we would see a slow sell off into September. Maybe to .15. However, holding the price and moving around 4MM shares a day is encouraging. That potential dilution should have sent the stock tumbling a bit in the short term. I like what I’m seeing this week. IMHO of course.

0 · Reply

MGeronimo Aug. 13 at 9:57 PM

$PCSA ADDING AT .22

0 · Reply

MGeronimo Aug. 13 at 9:38 PM

$PCSA ADDING THE DIP

0 · Reply

race2zero Aug. 13 at 9:06 PM

$PCSA well, well, well….a little green

0 · Reply

Paraplego Aug. 13 at 8:07 PM

$PCSA @race2zero Are you ready ? :D

0 · Reply

Jeffg1981 Aug. 13 at 6:55 PM

$PCSA a very SPECIAL meeting indeed. More dilution and a reverse split coming soon!

1 · Reply

paok44 Aug. 13 at 6:55 PM

$PCSA ΑΠΟ 4% ΠΑΕΙ 0% ΚΑΙ ΑΠΟ 0% ΠΑΕΙ 4% ΜΕ ΤΗΝ ΜΙΑ!!

0 · Reply

Whatwhatwhat100 Aug. 13 at 5:26 PM

$PCSA Straight ass this one

0 · Reply

littlegretti Aug. 13 at 3:51 PM

$PCSA Looks like it wants to go

1 · Reply

TheDrunkTrader69 Aug. 13 at 2:00 PM

$PCSA Whales not in but looking, I will say it again this is a buy all day down here

0 · Reply

Market Cap	10.88M
Revenue (ttm)	0.00
Net Income (ttm)	-11.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,982,400
Avg Vol	22,240,502
Day's Range	N/A - N/A
Shares Out	50.35M
Stochastic %K	31%
Beta	1.32
Analysts	Strong Sell
Price Target	$2.00